At a glance
No direct clinical trial of this catalogue combination was identified in the bounded search. Three component-only clinical/imaging references and one identity-only analytical paper provide background; none validates the supplied blend.
Identity & scope
The exact catalogue alias is Semax/Selank. The product's own labelled quantities and format remain separate specifications; component names alone do not verify blend composition, compatibility or stability.
What the research shows
- Human studies have examined Semax-related imaging changes and Selank-related symptom ratings independently.
- The study whose title names both peptides allocated participants to separate Semax, Selank or placebo groups. It cannot demonstrate synergy or combined-product effectiveness.
Critical interpretation
A two-name title is not a combination trial
A paper mentioning both peptides can still test them in separate groups. Such a design cannot establish an interaction between them. The relevant next experiment would compare a characterized mixture with each component and a suitable control, using the same predefined outcome. [1]
Identity evidence answers a separate question
Analytical identification is essential background, but even a correctly identified ingredient does not demonstrate a useful mixture. The forensic paper illustrates laboratory identification in other preparations; it neither certifies this catalogue blend nor supplies a combined-product trial. Ratio, stability and interactions remain separate open questions. [4]
Limitations & uncertainties
- Effects observed for one ingredient cannot be added together to predict a mixture's effects.
- The cited studies do not establish blend interactions, a combined safety profile or equivalence of a nasal product to another preparation.
- A combined name does not resolve independent identity, content, impurity, formulation or shelf-life questions for a supplied batch.
Open research questions
- Has a precisely characterized combined formulation been tested against its individual components and placebo?
- Does combining the peptides change exposure, stability, interactions or measured outcomes?
Selected papers & source records
Download bibliography1. Functional Connectomic Approach to Studying Selank and Semax Effects (opens in a new tab)
Panikratova YR et al. (2020). Dokl Biol Sci. DOI: 10.1134/S001249662001007X (opens in a new tab) · PMID 32342318
- Design & population
- Acute resting-state fMRI study in 52 healthy participants receiving Semax, Selank or placebo separately.
- What the study found
- The authors reported amygdala-to-temporal-cortex connectivity differences.
- Limits on interpretation
- Surrogate imaging endpoints; neither clinical effectiveness nor combined-blend effects established.
2. Effects of Semax on the Default Mode Network of the Brain (opens in a new tab)
Lebedeva IS et al. (2018). Bull Exp Biol Med. DOI: 10.1007/s10517-018-4234-3 (opens in a new tab) · PMID 30225715
- Design & population
- Resting-state fMRI experiment in 24 healthy adults, with Semax and placebo groups.
- What the study found
- The Semax group showed a larger rostral default-mode-network subcomponent.
- Limits on interpretation
- Small, acute imaging study; no established improvement in practical cognition.
3. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia (opens in a new tab)
Zozulia AA et al. (2008). Zh Nevrol Psikhiatr Im S S Korsakova. · PMID 18454096
- Design & population
- Clinical comparison of Selank and medazepam in 62 patients; PubMed indexes a randomized trial.
- What the study found
- The abstract reports similar anxiety-related effects between groups.
- Limits on interpretation
- Small active-comparator study; Russian full text not reviewed and no placebo arm described in the abstract.
4. The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations: An incentive for controlling agencies to prepare for future encounters of the kind (opens in a new tab)
Vanhee C et al. (2020). Drug Test Anal. DOI: 10.1002/dta.2717 (opens in a new tab) · PMID 31667971
- Design & population
- Analytical investigation of suspicious preparations and development of a mass-spectrometric screening method for research peptides.
- What the study found
- The investigators identified preparations containing the named peptides and developed analytical screening methods.
- Limits on interpretation
- These were other preparations, not HeartPep batches. Identification does not establish a combined formulation's effects, safety or stability.
Search & review scope
Searched for combination/blend trials and checked whether original reports administered the components together or separately. Initial selection on 8 November was substantively extended on 9 November, with clinical searches, accessible full-text consultation and bounded publication-notice checks.. Checked 9 November 2026.
Direct blend evidence sought; individually administered component studies retained for background.
A bounded search cannot prove that no combination research exists. The complete retrieved PubMed record for PMID32342318 showed no linked retraction/erratum section; some other record fetches were incomplete. No paper here establishes the supplied blend.
Recorded search terms
- site:pubmed.ncbi.nlm.nih.gov "Semax" "Selank" combination blend trial
- site:pubmed.ncbi.nlm.nih.gov/32342318/
- site:pubmed.ncbi.nlm.nih.gov/30225715/
- site:pubmed.ncbi.nlm.nih.gov/18454096/
- site:pubmed.ncbi.nlm.nih.gov/31667971/
Read the collection’s methods and editorial limits. For formal research, assess and cite the original paper.
Cite this review
HeartPep. Semax / Selank: blend review. HeartPep literature library. Reviewed 9 November 2026. https://heartpep.com/uk/research/library/semax-selank.
HeartPep is the commercial publisher of this secondary summary. It is not a peer-reviewed primary paper. Cite the original studies for their findings.
Buy from HeartPep.com
Laboratory research only. Not for human or veterinary use.